Enhanced Cytotoxicity of 5-FU by bFGF through Up-Regulation of Uridine Phosphorylase 1

  • Im, Young-Sam (Department of Biochemistry, College of Medicine, Chungbuk National University) ;
  • Shin, Hea Kyeong (Department of Plastic Surgery, College of Medicine, Dongguk University) ;
  • Kim, Hye-Ryun (Department of Biochemistry, College of Medicine, Chungbuk National University) ;
  • Jeong, So-Hee (Department of Biochemistry, College of Medicine, Chungbuk National University) ;
  • Kim, Seung-Ryul (Department of Biochemistry, College of Medicine, Chungbuk National University) ;
  • Kim, Yong-Min (Department of Orthopaedic Surgery, College of Medicine, Chungbuk National University) ;
  • Lee, Do Hyung (Gyeonggi Regional Research Center, Hankyoung National University) ;
  • Jeon, Seong-Ho (College of Pharmacy, Kangwon National University) ;
  • Lee, Hyeon-Woo (Department of Pharmacology, School of Dentistry, Kyung Hee University) ;
  • Choi, Joong-Kook (Department of Biochemistry, College of Medicine, Chungbuk National University)
  • Received : 2009.06.11
  • Accepted : 2009.07.10
  • Published : 2009.08.31


Anti cancer agent 5-FU (Fluoro Uracil) is a prodrug that can be metabolized and then activated to interfere with RNA and DNA homeostasis. However, the majority of administered 5-FU is known to be catabolized in vivo in the liver where Dihydropyrimidine dehydrogenase (DPD) is abundantly expressed to degrade 5-FU. The biological factors that correlate with the response to 5-FU-based chemotherapy have been proposed to include uridine phosphorylase (UPP), thymidine phosphorylase (TPP), p53 and microsatellite instability. Among these, the expression of UPP is known to be controlled by cytokines such as $TNF-{\alpha}$, IL1 and $IFN-{\gamma}$. Our preliminary study using a DNA microarray technique showed that basic fibroblast growth factor (bFGF) markedly induced the expression of UPP1 at the transcription level. In the present study, we investigated whether bFGF could modulate the expression of UPP1 in osteo-lineage cells and examined the sensitivity of these cells to 5-FU mediated apoptosis.


5-DFUR (= 5-dFURd);5-FU;apoptosis;ATDC5 chondroprogenitor cells;bFGF;C2C12 pre-myoblasts;$NF{\kappa}B$;uridine phosphorylase


Supported by : Korea Science and Engineering Foundation (KOSEF), Chungbuk National University


  1. Diasio, R.B., and Harris, B.E. (1989). Clinical pharmacology of 5- fluorouracil. Clin. Pharmacokinet. 16, 215-237
  2. Douillard, J.Y., Cunningham, D., Roth, A.D., Navarro, M., James, R.D., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355,1041-1047
  3. el Kouni, M.H., Naguib, F.N., Park, K.S., Cha, S., Darnowski, J.W., and Soong, S.J. (1990). Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice. Biochem. Pharmacol. 40, 2479-2485
  4. Voboril, R., Hochwald, S.N., Li, J., Brank, A., Weberova, J., Wessels, F., Moldawer, L.L., Camp, E.R., and MacKay, S.L. (2004). Inhibition of NF-kappa B augments sensitivity to 5- fluorouracil/folinic acid in colon cancer. J. Surg. Res. 120, 178-188
  5. Seymour, M.T., Slevin, M.L., Kerr, D.J., Cunningham, D., James, R.D., Ledermann, J.A., Perren, T.J., McAdam, W.A., Harper, P.G., Neoptolemos, J.P., et al. (1996). Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J. Clin. Oncol. 14, 2280-2288
  6. Baynes, J.W., and Dominiczak, M.H. (2005). Medical biochem-mistry (Elsevier Mosby), pp.417-423
  7. Kim, S., Park, D.H., and Shim, J. (2008). Thymidylate synthase and dihydropyrimidine dehydrogenase levels are associated with response to 5-fluorouracil in Caenorhabditis elegans. Mol. Cells 26, 344-349
  8. Giacchetti, S., Perpoint, B., Zidani, R., Le, B.N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J.F., Letourneau, Y., Coudert, B., et al. (2000). Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18,136-147
  9. Geng, Y., Gheuens, E., and de Bruijn, E.A. (1991). Activation and cytotoxicity of 5'-deoxy-5-fluorouridine in c-H-ras transformed NIH 3T3 cells. Biochem. Pharmacol. 41, 301-303
  10. Cao, D., and Pizzorno, G. (2004). Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation. Drugs Today (Barc.) 40, 431-443
  11. Lee, S.J., Lee, H.K., Cho, S.Y., Choi, J.K., Shin, H.K., Kwak, E.J., Cho, M.R., Kim, H.R., Kim, S.R., Kim, Y.M., et al. (2008). Identification of osteogenic purmorphamine deriva-tives. Mol. Cells 26, 380-386
  12. Al Safarjalani, O.N., Zhou, X.J., Rais, R.H., Shi, J., Schinazi, R.F., Naguib, F.N., and El Kouni, M.H. (2005). 5-(Phenylthio) acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. Cancer Chemother. Pharmacol. 55, 541-551
  13. Johnston, P.G., and Kaye, S. (2001). Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 12, 639-646
  14. Moyer, J.D., Oliver, J.T., and Handschumacher, R.E. (1981). Salvage of circulating pyrimidine nucleosides in the rat. Cancer Res. 41, 3010-3017
  15. Greco, F.A., Figlin, R., York, M., Einhorn, L., Schilsky, R., Marshall, E.M., Buys, S.S., Froimtchuk, M.J., Schuller, J., Schuchter, L., et al. (1996). Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J. Clin. Oncol. 14, 2674-2681
  16. Schwartz, E.L., Wan, E., Wang, F.S., and Baptiste, N. (1998). Regulation of expression of thymidine phosphorylase/plateletderived endothelial cell growth factor in human colon carcinoma cells. Cancer Res. 58, 1551-1557
  17. Wan, L., Cao, D., Zeng, J., Yan, R., and Pizzorno, G. (2006). Modulation of uridine phosphorylase gene expression by tumor necrosis factor-alpha enhances the antiproliferative activity of the capecitabine intermediate 5′-deoxy-5-fluorouridine in breast cancer cells. Mol. Pharmacol. 69, 1389-1395
  18. Longley, D.B., Harkin, D.P., and Johnston, P.G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330-338